Equine CCL5 (RANTES) Polyclonal Antibody - Biotinylated

The Equine CCL5 (RANTES) polyclonal antibody is labeled and has been qualified for use in ELISA. It is the detection antibody in the Kingfisher Biotech Equine CCL5 ELISA. The Equine CCL5 antibody was produced in rabbits and is antigen-affinity purified. The reactivity by species is: (Bovine CCL5 - Weak) (Canine CCL5 - None) (Dolphin CCL5 - None) (Equine CCL5 - Strong) (Guinea Pig CCL5 - None) (Swine CCL5 - Weak). For research use only.

Equine CCL5 (C-C motif chemokine ligand 5, also known as RANTES - Regulated upon Activation, Normal T cell Expressed and Secreted) is a proinflammatory chemokine that regulates immune cell recruitment and inflammatory responses in horses (Equus caballus). CCL5 is a member of the CC chemokine family, which also includes CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL2 (MCP-1), chemokines that coordinate leukocyte trafficking during immune activation. In horses, CCL5 is produced primarily by activated T lymphocytes, macrophages, dendritic cells, platelets, and epithelial cells in response to infection, inflammatory stimuli, or tissue injury, and it exerts its biological effects mainly through binding to the chemokine receptors CCR1, CCR3, and CCR5, promoting chemotaxis and activation of T cells, monocytes/macrophages, eosinophils, and natural killer (NK) cells at sites of inflammation. In equine health, CCL5 contributes to immune responses associated with respiratory diseases such as equine asthma (recurrent airway obstruction), viral infections, and inflammatory airway conditions, where chemokine-mediated recruitment of leukocytes to lung tissues is a key component of the inflammatory response. Because horses are commonly studied in respiratory disease, inflammatory disorders, and comparative immunology, equine CCL5 is investigated in research on chemokine-regulated leukocyte trafficking, airway inflammation, and immune responses to infectious and environmental triggers.

Choose a size

Price: $400.00

RELATED MEDIA